[J] .肺动脉高压患者口服药物治疗血流动力学正常化的治疗局限性[J] .欧洲呼吸杂志[J] .中华呼吸科学杂志[J] . 10.1183/13993003.大会-2019。PA5467 VL - 54 IS - supl - 63 SP - PA5467 AU - Hiroto Shimokawahara AU - Hiromi Matsubara AU - Kazuna Hayashi AU - Takahiro Nishihara AU - Masahiro Tsuji AU - Takanori Naito AU - Masataka Shigetoshi AU - Isao Tabuchi AU - Mitsuru Munemasa Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA5467.abstract N2 -背景:肺动脉高压(PAH)尽管有可用的治疗方案，但预后较差。血流动力学的正常化将需要获得良好的预后。目的和目的:我们的目的是研究PAH患者仅通过口服药物使血流动力学正常化的决定因素。方法:我们回顾性分析了在单一转诊中心治疗的190例PAH患者。观察治疗前后血流动力学参数。随访时将患者分为平均肺动脉压(mPAP)<30mmHg的良好对照组和平均肺动脉压≧30mmHg的不良对照组。结果:特发性/遗传性82例，结缔组织病65例，先天性心脏病22例，门静脉高压症21例。从基线到随访，mPAP显著下降(51±18.7 mmHg至34.1±15.2 mmHg, p<0.001)。不同病因间mPAP的降低无差异。与单纯口服前列腺素治疗组相比，联合口服前列腺素治疗组的mPAP下降幅度更大(22.5±2.0 mmHg vs.11.6±1.4 mmHg, p<0.001)。 Among the 76 patients treated with only oral drugs, mPAP before treatment in the poor control group was higher than that in another group (47.2 mmHg vs. 38.1 mmHg, p<0.001). The best cutoff value of mPAP before treatment for detecting mean PAP≦30mmHg after treatment was 39.5mmHg according to the receiver operating analysis (p=0.001).Conclusions: To achieve normalization of hemodynamics in PAH, parenteral prostanoid should be used in cases with baseline mPAP exceeding 40mmHg.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5467.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -